In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.
Miles Harrison
Advertisement
Miles Harrison is the president and CEO of Conexeu Sciences.
Articles by Miles Harrison
Conexeu is advancing its ECM-regenerating tissue tech, targeting wound care via FDA 510(k) and eyeing aesthetics, reconstruction, and beyond.
Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Q&A: Victoria Werth, MD, on Brepocitinib's FDA Approval for Dermatomyositis
4
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
5